World Oncology Cell Therapy Congress: USA 2023

OCTS USA 2023

The World Oncology Cell Therapy Congress: USA Returns In 2023

Register your interest

Thank you to our incredible speakers, partners and delegation for joining us at the 6th Annual Onco Cell Therapy Summit USA. We hope to welcome you to our sister event this November.

How To Get Involved

Partner With Us

It's never too early to get involved! Based on your objectives, we can create bespoke packages designed specifically for you.

From presenting your expertize on the main stage to hosting the infamous CAR-T Party. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.

Discuss your objectives with Ryan Sanderson, Commercial Partnerships Director[email protected]

OR REGISTER YOUR INTEREST IN SPONSORSHIP HERE.

Partner with Us

Register As A Delegate

Innovation in cell therapy for cancer is at an all-time high, with the exploration of autologous and allogeneic therapies derived from T cells, NK cells, macrophages and beyond.

Step into interactive discussions and engaging presentations on the hottest challenges facing the cell therapy industry today. 

Book here today at our pre-launch rate to benefit from the lowest available prices.

OR REGISTER YOUR INTEREST IN THE 2023 AGENDA HERE.

Register your interest

WHO WILL BE THERE

Network with industry experts from:

  • Senior-level leaders from biotech and representatives from big pharma
  • Academic experts in cell therapy
  • Process standardisation - technology/services
  • Logistics companies - cell storage/transport
  • Service providers – CROs, CDMOs, consultants, logistics companies and more

"New research was presented. The panels were educational and the small intimate setting was a plus."
TCR2 Therapeutics (Previous OCTS Attendee)

Last year's attendees included:

Previous Speakers

 

John Langowski

VP, Cell Biology
Kite Pharma

John Langowski

VP, Cell Biology
Kite Pharma

John Langowski

VP, Cell Biology
Kite Pharma
 

Peter Bross

Chief, Oncology Branch, Office of Tissues and Advanced Therapeutics, Center for Biologics Evaluation and Research
FDA

Peter Bross

Chief, Oncology Branch, Office of Tissues and Advanced Therapeutics, Center for Biologics Evaluation and Research
FDA

Peter Bross

Chief, Oncology Branch, Office of Tissues and Advanced Therapeutics, Center for Biologics Evaluation and Research
FDA
 

Crystal L Mackall MD

Director
Stanford Center for Cancer Cell Therapy

Ernest and Amelia Gallo Family Professor of Pediatrics and Medicine 

Director, Stanford Center for Cancer Cell Therapy 

Director, Parker Institute for Cancer Immunotherapy at Stanford 

Co-Executive Director, Stanford Laboratory for Cell and Gene Medicine 

Associate Director, Stanford Cancer Institute 

Crystal L Mackall MD

Director
Stanford Center for Cancer Cell Therapy

Crystal L Mackall MD

Director
Stanford Center for Cancer Cell Therapy

Ernest and Amelia Gallo Family Professor of Pediatrics and Medicine 

Director, Stanford Center for Cancer Cell Therapy 

Director, Parker Institute for Cancer Immunotherapy at Stanford 

Co-Executive Director, Stanford Laboratory for Cell and Gene Medicine 

Associate Director, Stanford Cancer Institute 

 

Arun Balakumaran

SVP, Head of Clinical Development
Allogene Therapeutics

Arun Balakumaran

SVP, Head of Clinical Development
Allogene Therapeutics

Arun Balakumaran

SVP, Head of Clinical Development
Allogene Therapeutics
 

Vered Caplan

CEO
Orgenesis

Vered Caplan

CEO
Orgenesis

Vered Caplan

CEO
Orgenesis
 

Birgit Schultes

Senior VP, Head of Cell Therapies
Intellia Therapeutics

Birgit Schultes

Senior VP, Head of Cell Therapies
Intellia Therapeutics

Birgit Schultes

Senior VP, Head of Cell Therapies
Intellia Therapeutics
 

Snehal Patel

SVP, Head of Manufacturing
Sana Biotechnology

Snehal Patel is the Global Head and Vice President for Cell Therapy Manufacturing for Bristol Myers Squibb (BMS). He leads the growing global manufacturing network to produce Clinical and Commercial Cell Therapy Products, including the two cell therapies recently launched in 2021 by BMS. Overseeing three state-of-the-art production facilities, Snehal is also closely involved in planning, development and construction of two additional facilities to continue expanding BMS’ global footprint. In addition, he has served as Site Head for Cell Therapy Manufacturing and is based in Seattle, WA.

Snehal Patel

SVP, Head of Manufacturing
Sana Biotechnology

Snehal Patel

SVP, Head of Manufacturing
Sana Biotechnology

Snehal Patel is the Global Head and Vice President for Cell Therapy Manufacturing for Bristol Myers Squibb (BMS). He leads the growing global manufacturing network to produce Clinical and Commercial Cell Therapy Products, including the two cell therapies recently launched in 2021 by BMS. Overseeing three state-of-the-art production facilities, Snehal is also closely involved in planning, development and construction of two additional facilities to continue expanding BMS’ global footprint. In addition, he has served as Site Head for Cell Therapy Manufacturing and is based in Seattle, WA. He started at BMS via the Juno Therapeutics acquisition in February 2018.

Prior to joining BMS, Snehal worked at Genentech/Roche for ~18 years, holding a variety of different roles with increasing responsibility, including Head of Global External Drug Product Manufacturing, Head of Drug Product Operations, and Head of Quality Operations.

Snehal has a breadth of knowledge and experience including leadership roles in Technical Operations, Technology, Training, and Quality Assurance in Biologics, Small Molecules, and Cell Therapy. He is routinely sought out for his technical expertise, as well as his ability to collaborate and influence. He is a dynamic leader where he focuses on Inspirational Leadership and Development of his team.

 

Serena De Vita

Clinical Program Leader & Senior Director
Novartis Institutes for BioMedical Research

Serena De Vita

Clinical Program Leader & Senior Director
Novartis Institutes for BioMedical Research

Serena De Vita

Clinical Program Leader & Senior Director
Novartis Institutes for BioMedical Research
 

Debora Barton, MD

Chief Medical Officer
Carisma Therapeutics Inc.

Debora Barton, MD

Chief Medical Officer
Carisma Therapeutics Inc.

Debora Barton, MD

Chief Medical Officer
Carisma Therapeutics Inc.
 

Kate Rochlin

Chief Operating Officer
In8Bio

Kate Rochlin

Chief Operating Officer
In8Bio

Kate Rochlin

Chief Operating Officer
In8Bio
 

Christopher Pastorello

Director, Head of GMP Operations
Century

Christopher Pastorello

Director, Head of GMP Operations
Century

Christopher Pastorello

Director, Head of GMP Operations
Century
 

Robbie Majzner

Assistant Professor, Pediatrics
Stanford University School of Medicine

Robbie Majzner

Assistant Professor, Pediatrics
Stanford University School of Medicine

Robbie Majzner

Assistant Professor, Pediatrics
Stanford University School of Medicine
 

Eric Halioua

CEO
PDC*Line pharma

Eric Halioua

CEO
PDC*Line pharma

Eric Halioua

CEO
PDC*Line pharma
 

Cheng Liu

Founder, President and CEO
Eureka

Cheng Liu

Founder, President and CEO
Eureka

Cheng Liu

Founder, President and CEO
Eureka
 

Carnley Norman

Vice President of Global Manufacturing Sciences and Technology (MSAT)
Kite Pharma

Carnley Norman

Vice President of Global Manufacturing Sciences and Technology (MSAT)
Kite Pharma

Carnley Norman

Vice President of Global Manufacturing Sciences and Technology (MSAT)
Kite Pharma
 

Austin Boesch

Director, Head of Protein Sciences
Tidal Therapeutics

Austin Boesch

Director, Head of Protein Sciences
Tidal Therapeutics

Austin Boesch

Director, Head of Protein Sciences
Tidal Therapeutics
 

Christian Hinrichs

Chief of the Section of Cancer Immunotherapy
Rutgers Cancer Institute of New Jersey

Christian Hinrichs

Chief of the Section of Cancer Immunotherapy
Rutgers Cancer Institute of New Jersey

Christian Hinrichs

Chief of the Section of Cancer Immunotherapy
Rutgers Cancer Institute of New Jersey
 

Stefanie Bailey

Research Fellow
Massachusetts General Hospital and Harvard Medical School

Stefanie Bailey

Research Fellow
Massachusetts General Hospital and Harvard Medical School

Stefanie Bailey

Research Fellow
Massachusetts General Hospital and Harvard Medical School
 

Michael Leek

Co-founder and Executive Chair
TC Biopharm

Michael Leek

Co-founder and Executive Chair
TC Biopharm

Michael Leek

Co-founder and Executive Chair
TC Biopharm
 

Paul Rennert

Acting CEO, President, CSO
Aleta Biotherapeutics

Paul Rennert

Acting CEO, President, CSO
Aleta Biotherapeutics

Paul Rennert

Acting CEO, President, CSO
Aleta Biotherapeutics
 

Guanglin Yu

Senior Expert Science & Technology
Novartis

Guanglin Yu

Senior Expert Science & Technology
Novartis

Guanglin Yu

Senior Expert Science & Technology
Novartis
 

Adham Bear

Instructor of Medicine
Division of Hematology and Oncology, Hospital of the University of Pennsylvania

Adham Bear

Instructor of Medicine
Division of Hematology and Oncology, Hospital of the University of Pennsylvania

Adham Bear

Instructor of Medicine
Division of Hematology and Oncology, Hospital of the University of Pennsylvania
 

Moonsoo Jin

Professor of Biomedical Engineering in Radiology, Radiology; Co-founder
Weill Cornell Medical College; Affyimmune

Moonsoo Jin

Professor of Biomedical Engineering in Radiology, Radiology; Co-founder
Weill Cornell Medical College; Affyimmune

Moonsoo Jin

Professor of Biomedical Engineering in Radiology, Radiology; Co-founder
Weill Cornell Medical College; Affyimmune
 

Mark Yarmarkovich

Senior Scientist
Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia

Mark Yarmarkovich

Senior Scientist
Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia

Mark Yarmarkovich

Senior Scientist
Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia
 

Jorge Mansilla-Soto

Senior Research Scientist
The Michel Sadelain Lab, Sloan Kettering Insititute, Memorial Sloan Kettering Cancer Center

Jorge Mansilla-Soto

Senior Research Scientist
The Michel Sadelain Lab, Sloan Kettering Insititute, Memorial Sloan Kettering Cancer Center

Jorge Mansilla-Soto

Senior Research Scientist
The Michel Sadelain Lab, Sloan Kettering Insititute, Memorial Sloan Kettering Cancer Center
 

John Lu

President and CEO
HebeCell

John Lu

President and CEO
HebeCell

John Lu

President and CEO
HebeCell
 

Branden Moriarity

Chief Innovation Officer
Luminary Therapeutics

Branden Moriarity

Chief Innovation Officer
Luminary Therapeutics

Branden Moriarity

Chief Innovation Officer
Luminary Therapeutics
 

Jan ter Meulen

CSO
Obsidian Therapeutics

Jan ter Meulen

CSO
Obsidian Therapeutics

Jan ter Meulen

CSO
Obsidian Therapeutics
 

Gavin MacBeath

CSO
Tscan Therapeutics

Gavin MacBeath

CSO
Tscan Therapeutics

Gavin MacBeath

CSO
Tscan Therapeutics
 

Alba Gonzalez

Associate Director R&D
Senti Bio

Alba Gonzalez

Associate Director R&D
Senti Bio

Alba Gonzalez

Associate Director R&D
Senti Bio
 

Amanda Conerty

Executive Director of Analytical, Process development and Manufacturing
Artiva Biotherapeutics

Amanda Conerty

Executive Director of Analytical, Process development and Manufacturing
Artiva Biotherapeutics

Amanda Conerty

Executive Director of Analytical, Process development and Manufacturing
Artiva Biotherapeutics
 

David Brochu

CTO
Autolus Therapeutics

David Brochu

CTO
Autolus Therapeutics

David Brochu

CTO
Autolus Therapeutics
 

Jeffrey S Miller

Professor of Medicine, Division of Hematology, Oncology and Transplantation
University of Minnesota Medical School

Jeffrey S Miller

Professor of Medicine, Division of Hematology, Oncology and Transplantation
University of Minnesota Medical School

Jeffrey S Miller

Professor of Medicine, Division of Hematology, Oncology and Transplantation
University of Minnesota Medical School
 

Jennifer Buell

President and CEO
MiNK Therapeutics

Jennifer Buell

President and CEO
MiNK Therapeutics

Jennifer Buell

President and CEO
MiNK Therapeutics
 

Lucas de Breed

Founder
August Care

Lucas de Breed

Founder
August Care

Lucas de Breed

Founder
August Care
 

Matthew Li

Director
Tome Biosciences

Matthew Li

Director
Tome Biosciences

Matthew Li

Director
Tome Biosciences
 

Gail Turner

Senior Principal Scientist, Preclinical Sciences, Immune Oncology and Cell Therapy Thematic Research Center
Bristol Myers Squibb

Gail Turner

Senior Principal Scientist, Preclinical Sciences, Immune Oncology and Cell Therapy Thematic Research Center
Bristol Myers Squibb

Gail Turner

Senior Principal Scientist, Preclinical Sciences, Immune Oncology and Cell Therapy Thematic Research Center
Bristol Myers Squibb
 

Melissa Sebok

Executive Director – Product, Client & Business Development, Direct Patient Care & Emerging Offerings
American Red Cross

Melissa Sebok

Executive Director – Product, Client & Business Development, Direct Patient Care & Emerging Offerings
American Red Cross

Melissa Sebok

Executive Director – Product, Client & Business Development, Direct Patient Care & Emerging Offerings
American Red Cross
 

Reagan Jarvis

CEO
Anocca AB

Reagan Jarvis

CEO
Anocca AB

Reagan Jarvis

CEO
Anocca AB
 

Markus Gruell

Site Quality Head, Qualified Person
Autolus

Markus Gruell

Site Quality Head, Qualified Person
Autolus

Markus Gruell

Site Quality Head, Qualified Person
Autolus
 

Robert Tighe

Vice President, Research
TCR2 Therapeutics

Robert Tighe

Vice President, Research
TCR2 Therapeutics

Robert Tighe

Vice President, Research
TCR2 Therapeutics
 

Christina Bailey

Director, Cell and Gene Therapy, NanoString Technologies
Nanostring

Christina Bailey

Director, Cell and Gene Therapy, NanoString Technologies
Nanostring

Christina Bailey

Director, Cell and Gene Therapy, NanoString Technologies
Nanostring
 

Laura Johnson

Chief Scientific Officer
Verismo Therapeutics

Laura Johnson

Chief Scientific Officer
Verismo Therapeutics

Laura Johnson

Chief Scientific Officer
Verismo Therapeutics
 

Steven Doares

SVP & Site Head, US Manufacturing
Cellectis

Steven Doares

SVP & Site Head, US Manufacturing
Cellectis

Steven Doares

SVP & Site Head, US Manufacturing
Cellectis
 

Pete Smith

CEO
Myrio Tx

Pete Smith

CEO
Myrio Tx

Pete Smith

CEO
Myrio Tx
 

Breanna DiAndreth

Scientist II
A2 Biotherapeutics

Breanna DiAndreth

Scientist II
A2 Biotherapeutics

Breanna DiAndreth

Scientist II
A2 Biotherapeutics
 

Subhadra Jayaraman

Senior Scientist I
Mammoth Biosciences

Subhadra Jayaraman

Senior Scientist I
Mammoth Biosciences

Subhadra Jayaraman

Senior Scientist I
Mammoth Biosciences
 

Lucia Poncette

Director, TCR Discovery
T-Knife Therapeutics

Lucia is T-knife‘s Director TCR discovery and is one of its founding scientists. She studied Human Biology in Marburg and Toowoomba (Australia) and obtained a doctor’s degree in tumor immunology from the Free University of Berlin followed by a PostDoc at the Max Delbrück Center for Molecular Medicine in Berlin. For the last 10 years Lucia has studied T cell receptors and their application in the treatment of cancer. At T-knife Lucia oversees the early development and characterization of T cell receptors using T-knife‘s proprietary myT platform.

Lucia Poncette

Director, TCR Discovery
T-Knife Therapeutics

Lucia Poncette

Director, TCR Discovery
T-Knife Therapeutics

Lucia is T-knife‘s Director TCR discovery and is one of its founding scientists. She studied Human Biology in Marburg and Toowoomba (Australia) and obtained a doctor’s degree in tumor immunology from the Free University of Berlin followed by a PostDoc at the Max Delbrück Center for Molecular Medicine in Berlin. For the last 10 years Lucia has studied T cell receptors and their application in the treatment of cancer. At T-knife Lucia oversees the early development and characterization of T cell receptors using T-knife‘s proprietary myT platform.

 

Stefania Gobessi

Director, Discovery
Gadeta BV

Stefania Gobessi

Director, Discovery
Gadeta BV

Stefania Gobessi

Director, Discovery
Gadeta BV
 

Raymond Luke

Director, Manufacturing Science and Technology
Verismo Therapeutics

Raymond Luke

Director, Manufacturing Science and Technology
Verismo Therapeutics

Raymond Luke

Director, Manufacturing Science and Technology
Verismo Therapeutics
 

Vineet Kacker

Managing Director
APCER Life Sciences, Inc.

Vineet Kacker

Managing Director
APCER Life Sciences, Inc.

Vineet Kacker

Managing Director
APCER Life Sciences, Inc.
 

Ashish Kothari

VP, Clinical Development, Cell Transplant Therapy
CareDx

Ashish Kothari

VP, Clinical Development, Cell Transplant Therapy
CareDx

Ashish Kothari

VP, Clinical Development, Cell Transplant Therapy
CareDx
 

Nissim Darvish

Venture Partner, OrbriMed & Managing General Partner
MeOhr Ventures

Nissim Darvish

Venture Partner, OrbriMed & Managing General Partner
MeOhr Ventures

Nissim Darvish

Venture Partner, OrbriMed & Managing General Partner
MeOhr Ventures
 

David Moskowitz

Principal
8VC

David Moskowitz

Principal
8VC

David Moskowitz

Principal
8VC
 

Ansbert Gadicke

Managing Director, MPM Capital – Managing Partner
BioImpact Capital

Ansbert Gadicke

Managing Director, MPM Capital – Managing Partner
BioImpact Capital

Ansbert Gadicke

Managing Director, MPM Capital – Managing Partner
BioImpact Capital
 

Philip Lee

CTO & Co-founder
Senti Biosciences

Philip Lee

CTO & Co-founder
Senti Biosciences

Philip Lee

CTO & Co-founder
Senti Biosciences
 

Jennifer McDevitt

VP, Clinical Sciences
ArsenalBio

Jennifer McDevitt

VP, Clinical Sciences
ArsenalBio

Jennifer McDevitt

VP, Clinical Sciences
ArsenalBio
 

David Ferrick

PhD., Chief Scientific Officer
Axion Biosystems Inc.

David Ferrick

PhD., Chief Scientific Officer
Axion Biosystems Inc.

David Ferrick

PhD., Chief Scientific Officer
Axion Biosystems Inc.
 

Brian Newsom

Senior Director of Business Development for Cell Therapy
KBI Biopharma

Brian Newsom

Senior Director of Business Development for Cell Therapy
KBI Biopharma

Brian Newsom

Senior Director of Business Development for Cell Therapy
KBI Biopharma
 

Jens Eberlein

Technical Lead, Immuno-Oncology
LUMICKS

Jens Eberlein

Technical Lead, Immuno-Oncology
LUMICKS

Jens Eberlein

Technical Lead, Immuno-Oncology
LUMICKS

Register Your Interest

The agenda for the Onco Cell Therapy Summit 2023 will be released very soon.

Fill out this form to register your interest and be the first to recieve the agenda when it becomes available!

REGISTER YOUR INTEREST

Mission Statement

The World Oncology Cell Therapy Congress (April 2023) USA is the only annual meeting bringing together drug developers, investors, solution providers and clinicians whose purpose is to deliver safe and effective adoptive cell therapy products to clinical implementation.

Demonstrating the value of innovative cell therapy products and securing access for patients is a key priority for all developers. In 2023, the World OCT Summit will become the only industry forum to add an exclusive pre-event evening networking session for clinicians looking to overcome barriers to patient access and facilitate clinical distribution of transformative cell therapy products. The congress will also redefine industry networking, with every attendee incentivised to complete a profile, enabling everyone to find and touch base with the pioneers and companies they would like to meet.

The congress schedule will also be revamped and be repositioned to reflect the dynamic research environment of the cell therapy field. Our on-stage talks, panels and Q&As will come under the following themes – ‘Breakthroughs and Pipeline Advancements’, ‘New Cell Therapy Platforms and Enabling Technologies’, ‘Manufacturing at Scale and Commercialization’ – and with our pre-event evening expanding into ‘Cell Therapy Access and Clinical Trial Delivery’.

Previous Partners

Platinum Partner

Gold Partners

Event Partners

Exhibitors

Media Partners

Non-Profit Partner

PARTNER WITH US

Based on your objectives, we can create bespoke packages designed specifically for you. From presenting your expertize on the main stage to hosting the infamous CAR-T Party. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.

Discuss your objectives with James Tappenden, Sales Director; [email protected] or Oleksiy Ihnatenko, Commercial Partnerships[email protected].

Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact Laura Hobson, Senior Marketing Manager; [email protected]

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Wednesday, July 27, 2022 to Friday, November 18, 2022
Tier 1 - Academics
$899
Pre-launch price
Wednesday, July 27, 2022 to Friday, November 18, 2022
Tier 2 - Biotech & Pharma
$1499
Pre-launch price
Wednesday, July 27, 2022 to Friday, November 18, 2022
Tier 3 - Service Provider
$2799
Pre-launch price
Preparing registration...

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 5% Off
Book a Team of 5+ - Save an Additional 10% Off
Book a Team of 10+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

Terms & Conditions

In the event that Kisaco Research postpones an event for any reason or changes the event format to ‘virtual event’, any in-person registrations for this event will be automatically transferred to the virtual registration package. The delegate will receive a credit note for the difference in ticket value from the fee paid. You may use this credit for another Kisaco Research event to be mutually agreed with Kisaco Research, which must occur within 12 months from the date of the event which the delegate had originally registered for.

Resources

Download Resource

Returning Safely Measures

Whether sponsors, speakers or attendees, our customers attend Kisaco Research events to connect, learn and innovate to know more and do business. It is our commitment that as we return to in-person events, they can do this effectively, safely and with confidence.

All in-person Kisaco Research events will prioritize the health and safety of colleagues and customers and, in the first instance, will be run in accordance with official government and local authority guidance, as well as any venue or location-specific regulations.

Kisaco Research is committed to following the Association of Event Organisers All Secure Standard, which has been approved by by UK Government.

Download the Kisaco Research Returning Safely Measures 

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us